You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Low-temperature chemical looping reforming catalysts for small-footprint GTL

    SBC: CATALYTIC AND REDOX SOLUTIONS LLC            Topic: 22a

    Methane from U.S. shale deposits has significantly increased the usable amount of this domestic energy resource. Meanwhile, flaring of natural gas, which is commonly practiced in shale-oil production, exceeded 6 billion cubic meters in the United State annually. This leads to a waste of valuable energy resources and significant emissions of greenhouse gas. As such, small-footprint technologies tha ...

    STTR Phase I 2019 Department of Energy
  2. No Stress PFC Bonding Technology

    SBC: SEALED OPTICS COMPANY            Topic: 23a

    Electric power generation regularly necessitates the conversion of heat into useful work. Except for some renewable forms, all energy production involves high-temperature. In cases such as fusion, fission, gas-turbine, and fuel cells, the operating temperatures can be very high. Working parts exposed to these environments are thermally stressed. The material joints found in multi-component parts m ...

    STTR Phase I 2019 Department of Energy
  3. Very High Field Hybrid Superconducting Magnet Using Bi-2212

    SBC: CRYOMAGNETICS INC            Topic: 26b

    High energy physics research, modern medicine and advanced materials are continually demanding stronger magnetic fields. Efforts to generate fields in excess of 25 Tesla have been a principal driver of High Temperature Superconductor research. Although HTS materials were discovered decades ago and have always shown significant potential for high field use, until recently magnets using the technolo ...

    STTR Phase II 2019 Department of Energy
  4. Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

    SBC: Initos Pharmaceuticals LLC            Topic: NCATS

    ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapies

    SBC: Alterna Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Despite recent advances in targeting cancer cellschemotherapy remains a mainstay of oncologyextending survival and providing cures for many types of cancerHoweverchemotherapy that ablates or suppresses bone marrow cells can be debilitating even when combined with autologous hematopoietic stem cell transplantationHSCTThe treatment causes severe side effects such as anemianeutropenia and th ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Automated CRISPR Screening Using the CellRaft Technology

    SBC: CELL MICROSYSTEMS INC            Topic: 400

    Project SummaryGenome wide functional genetics has been recently made possible by pooled library based CRISPR Casgene editing technologyBy randomly knocking out thousands of geneslarge scale screens can be conducted for functional geneticsdrug sensitivity and other phenotypesCurrently howeverthis forward genetic approach is largely relegated to live dead screens in mammalian cellsImproving the sop ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryInfectious disease is the third leading cause of death in the United Statesand hospital acquired infectionsHAIsin particular affectmillion patients annuallyThe most common type of HAI is pneumoniaoften caused by multi drug resistantMDRpathogens such as Staphylococcus aureusPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliand Acinetobacter baumanniiRates of antibiotic resis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. MegaTrans- human transporter machine learning models

    SBC: COLLABORATIONS PHARMACEUTICALS INC            Topic: 400

    Summary Being able to predict interactions with important human transporters would be of value to new drug design to avoid compounds that interact with them and cause undesirable side effectsOATP BSLCO Band OATP BSLCO Bare `uptakeandapostransporters largely restricted to the sinusoidal aspect of hepatocytesThey both transport a wide variety of structurally unrelated compoundsincluding members of s ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government